Loading
In bowel cancers that start on the left and have normal RAS and BRAF genes, adding an EGFR antibody to chemotherapy gives the longest survival seen in first-line trials.
PARADIGM: OS 37.9 months with panitumumab + mFOLFOX6 in left-sided RAS wild-type disease. FIRE-3 and CALGB 80405 subgroups agree. Right-sided or RAS/BRAF-mutant tumours should get bevacizumab instead. Anti-EGFR rechallenge after a chemotherapy-free interval, guided by ctDNA showing RAS/EGFR clones have receded (CHRONOS), is an emerging strategy.
Shares PARADIGM, CRYSTAL & FIRE-3, Sidedness (left vs right colon), FOLFIRI (5-FU, leucovorin, irinotecan).
Shares PARADIGM, CRYSTAL & FIRE-3, Sidedness (left vs right colon), Panitumumab.
Shares Panitumumab, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares PARADIGM, Sidedness (left vs right colon), Panitumumab, FOLFIRI (5-FU, leucovorin, irinotecan).
Shares CRYSTAL & FIRE-3, Sidedness (left vs right colon), FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab.
Shares PARADIGM, CRYSTAL & FIRE-3, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin).
Shares CRYSTAL & FIRE-3, Sidedness (left vs right colon), FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab.
Shares Sidedness (left vs right colon), Panitumumab, Cetuximab, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/